News Items

May is Brain Tumor Awareness Month, and Barrow Neurological Foundation is ramping up its efforts to raise funds for cutting-edge research at...

The Ivy Brain Tumor Center announces the activation of a new clinical trial evaluating a B7-H3-targeted antibody-drug conjugate (ADC), risvutatug rezetecan (Ris-Rez), in recurrent grade 4 glioma and brain metastases. Ris-Rez is designed to deliver a therapeutic payload to tumor cells that express B7-H3.

An impressive $5.1 million was raised specifically through the Ball to help advance critical research at the Ivy Center.

Last week, the Ivy Brain Tumor Center published a manuscript in Science Translational Medicine authored by Nader Sanai, MD, Shwetal Mehta, PHD, Artak Tovmasyan, PHD, An-Chi Tien, PHD, Igor Barani, MD, Charuta Furey, MD, and Zaman Mirzadeh, MD, in collaboration with other Ivy Center team members. The manuscript presents results from our early phase clinical trial utilizing sonodynamic therapy (SDT) in recurrent high-grade glioma patients. SDT pairs 5-aminolevulinic acid (5-ALA), which is metabolized to protoporphyrin IX in glioma cells, with noninvasive, image-guided focused ultrasound to trigger tumor-selective oxidative injury.

The U.S. FDA has granted ODD to niraparib for the treatment of malignant glioma, including GBM. The designation is supported...

This week, the Ivy Brain Tumor Center published a manuscript in the Oxford University Press on behalf of the Society for NeuroOncology. The manuscript was authored by Nader Sanai, MD, Shwetal Mehta, PHD, and Roel G.W. Verhaak, PHD, in collaboration with other Ivy Center team members. The manuscript illustrates the results of our Phase 0/1 clinical trial combining two targeted drugs ribociclib (CDK4/6 inhibitor) and everolimus (mTOR inhibitor) in recurrent high-grade glioma patients, aiming to identify brain-penetrant combinations and assess their impact on malignant cell states.

Dr. Nader Sanai and the Ivy Brain Tumor Center were featured on MLB.com to highlight Brain Tumor Awareness Night at Chase Field on May 6, 2025. The article covers the Nicole Hazen Fund for Hope’s donation to the Ivy Center and the Center’s accelerated glioblastoma research—spotlighting the rapid progress of the niraparib study toward a global Phase 3 trial. Read the full story to learn how this partnership is driving new hope for brain tumor patients and their families.

Dr. William Kennedy, a neuroradiation oncologist at the Ivy Brain Tumor Center at Barrow Neurological Institute, was recently featured on CancerNetwork’s “Oncology on the Go” podcast. In the episode, Dr. Kennedy discusses the role of noninvasive radiosurgery in treating central nervous system (CNS) tumors, including glioblastoma. Listen now!

Cancer Research UK recently highlighted the Ivy Brain Tumor Center for its groundbreaking work in glioblastoma research. Led by Dr. Nader Sanai, whose personal connection to the disease drives his passion, the Ivy Center is at the forefront of developing innovative treatments for brain cancer. With a focus on overcoming challenges such as limited drug development and complex tumor biology, the Ivy Center is committed to advancing therapies that can improve the lives of patients with glioblastoma.

Dr. Shewetal Mehta, PhD, Deputy Director at the Ivy Brain Tumor Center, discusses cutting-edge brain cancer research with CancerNetwork®. She shares insights on early-phase clinical trials, including a phase 0/1 trial for BDTX-1535, an EGFR inhibitor for high-grade glioma, and the importance of biomarker testing in personalizing treatment. Dr. Mehta also explores the potential of new therapies like proteolysis targeting chimeras and antibody-drug conjugates. Explore more by watching her mini-episodes now.